Shanghai, China

Ya Kong

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Antengene Discovery Limited. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ya Kong. Retrieved from https://idiyas.com/inventor/ya-kong-2kycbiyi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Ya Kong

Introduction

Ya Kong is an accomplished inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that inhibit PRMT5. His work is crucial in the ongoing fight against various diseases, including cancers.

Latest Patents

Ya Kong holds a patent for "PRMT5 inhibiting compounds and uses thereof." This patent provides novel PRMT5 and/or MTA-cooperative PRMT5 inhibiting compounds, or pharmaceutically acceptable salts thereof. The application also details pharmaceutical compositions that include these compounds as active ingredients, highlighting their potential use in treating diseases or disorders, including cancers. He has 1 patent to his name.

Career Highlights

Ya Kong is currently employed at Antengene Discovery Limited, where he continues to innovate and develop new therapeutic solutions. His expertise in the field has positioned him as a key player in the pharmaceutical industry.

Collaborations

Ya Kong collaborates with talented individuals such as Ming Zhang and Lulu Jiang, who contribute to the research and development efforts at Antengene Discovery Limited.

Conclusion

Ya Kong's work exemplifies the impact of innovative research in the pharmaceutical industry. His contributions to PRMT5 inhibiting compounds are paving the way for new treatments in cancer therapy.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…